2020
DOI: 10.1111/dth.13417
|View full text |Cite
|
Sign up to set email alerts
|

Secukinumab‐induced subacute cutaneous lupus erythematosus

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 6 publications
0
9
0
Order By: Relevance
“…Secukinumab was stopped, and topical mometasone furoate cream and prednisolone cream cleared lupus erythematosus after about 8 weeks. Two other similar cases were diagnosed in a 58‐year‐old woman 6 and a 62 year‐old‐man 46 after 1 month of secukinumab treatment for Ps. Unlike classic lupus erythematosus, patients with drug‐induced lupus erythematosus generally recover within weeks (sometimes months) after discontinuation of the putative offending drug, which is the best evidence for this diagnosis 93 .…”
Section: Discussionmentioning
confidence: 89%
See 2 more Smart Citations
“…Secukinumab was stopped, and topical mometasone furoate cream and prednisolone cream cleared lupus erythematosus after about 8 weeks. Two other similar cases were diagnosed in a 58‐year‐old woman 6 and a 62 year‐old‐man 46 after 1 month of secukinumab treatment for Ps. Unlike classic lupus erythematosus, patients with drug‐induced lupus erythematosus generally recover within weeks (sometimes months) after discontinuation of the putative offending drug, which is the best evidence for this diagnosis 93 .…”
Section: Discussionmentioning
confidence: 89%
“…The onset time of those AESI ranged from 3 days 52 to 96 weeks 60 . A total of 24 AESI was identified (Table 1), including adiposity, 14 alopecia areata, 15 acute autoimmune hemolytic anemia, 16 bullous eruption, 17,18,32 crystalline corneal deposition, 19 drug‐associated vasculitis (including leucocytoclastic vasculitis, IgA vasculitis [henoch‐schönlein purpura], and Behcet's disease), 5,20–24,61 eczematous drug eruption, 11,25–31,62 erectile dysfunction, 35 granuloma annulare, 36–38 hidradenitis suppurativa, 39,40 hypertrichosis, 41 IBD (including Crohn disease [CD], ulcerative colitis [UC], and IBD undefined [IBDU]), 9,12,13 interstitial pneumonia, 42,43 drug‐induced lupus erythematosus, 6,45–47 multiple lentigines, 48 perianal dermatophytosis, 51 pompholyx (dyshidrotic eczema), 33,34 pseudolymphoma, 52 pyoderma gangrenosum, 53,54 raynaud's phenomenon, 55 scleroderma, 57 stomatitis (such as lichenoid mucositis, oral lichen planus, and angular cheilitis), 44,49,50,56 uveitis, 58 and vitiligo 59,60 …”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Particularly relevant to the rheumatologist is the potential for biologic therapies including TNF- inhibitors, IL-17 inhibitors, IL-12/23 inhibitors and cytotoxic T-lymphocyte associated protein-4 therapy to induce SCLE. [39][40][41][42] Rowell's syndrome is an entity that can be associated with SLE, DLE, or SCLE, in which patients develop erythema multiforme-like lesions and have a speckled ANA pattern. 25 Sjogren's syndrome is often a concomitant autoimmune disorder found in patients with SCLE and is more commonly associated with SCLE than other CLE subtypes.…”
Section: Subacute Cutaneous Lupus Erythematosusmentioning
confidence: 99%
“…Brodalumab, ixekizumab and secukinumab target the IL‐17 pathway, with the former targeting directly at the IL‐17A receptor and the latter two inhibiting IL‐17A 1 . There are only three cases of secukinumab‐induced LE reported in the literature 2–4 . To our knowledge, there is no report to date on SCLE associated with brodalumab.…”
Section: Figurementioning
confidence: 99%